The brain-chip model was treated with a small-molecule inhibitor of the MEK1/2 pathway and LRRK2 mutation, both characteristic of Parkinson’s disease pathology, to modulate inflammation and angiogenesis. This evidence concerns the gene MAP2K1 and Parkinson disease.